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SUMMARY 
One of the biggest and most important challenges of modern science is to defeat 
cancer. Decades of research have significantly improved the therapeutic outcome, yet 
have failed to satisfactorily control all of the different types of cancer. The reasons are 
most likely due to the heterogeneity of the development of cancer: mutations, 
epigenetic changes, abnormalities and defects in multiple different genes and proteins 
can lead to aberrant cell behavior, that can ultimately result in the disease called 
“cancer”. Radiotherapy is a standard treatment strategy for cancer patients, applied 
alone or in combination with other treatment regimes, and mostly aims to kill tumor 
cells by DNA damage. Interestingly, tumor cells exposed to ionizing radiation release 
several factors into the tumor microenvironment where they influence signaling 
cascades in an auto- and/or paracrine fashion. Radiotherapy kills a clear majority of 
tumor cells, but also induces a multilayered stress response that may interfere with 
optimal treatment outcome.  
In foresight to the development of novel drug targets that can be used to improve 
radiotherapy, my thesis focuses on the intra- and intercellular signaling pathways 
orchestrated by the metalloproteinase ADAM17. ADAM17 is localized on the outer side 
of the plasma membrane and cleaves multiple factors involved in tumor progression 
and inflammation. In several cancer types, ADAM17 expression is increased compared 
to healthy tissue and correlates with poor prognosis. Our previous studies also 
implicated ADAM17’s role in radiosensitizing cells towards ionizing radiation.  
In a first part, I aimed to identify the role of a shRNA-mediated downregulation of 
ADAM17 in two different NSCLC cell lines (A549 and H358) in response to IR. 
Downregulation of the protein levels concomitantly resulted in decreased enzyme 
activity and subsequent ligand shedding. Additionally, ADAM17-depleted cells showed 
decreased proliferative activity and clonogenic survival in a dose-dependent way. 
Based on this evidence, we conclude that ADAM17 is involved in mechanisms 
influencing efficacy of ionizing radiation.  
In a second part, we investigated ADAM17’s effect on intra- and intercellular signaling 
affecting migration. Astonishingly, migration was increased towards a secretome full of 
ADAM17-cleaved factors as compared to an ADAM17-cleaved factor scarce 
secretome. These results indicate an involvement of ADAM17-cleaved factors in intra- 
and intercellular communication affecting migration.  
In conclusion, the thesis underlines the undeniable involvement of ADAM17 in 
orchestrating radioresistance. Additionally, it helps to further explain the intra- and 
intercellular regulatory mechanisms facilitated by ADAM17. Altogether, the work of this 
thesis supports the rational of combining radiotherapy with a potent ADAM17 inhibitor 
to improve treatment outcome.  
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ZUSAMMENFASSUNG 
Die Bekämpfung von Krebs zählt heutzutage zu den grössten wissenschaftlichen 
Herausforderungen. Jahrzehntelange Forschung hat die Krebsbehandlung signifikant 
verbessert, allerdings können bis heute nicht alle Tumore in einer befriedigenden 
Weise kontrolliert werden. Die Gründe dafür liegen mit grösster Wahrscheinlichkeit in 
der enormen Vielfältigkeit der Entstehung von Tumoren. Mutationen, Abnormalitäten 
und Defekte in vielen verschiedenen Genen und Proteinen können zu anormalem 
Zellverhalten führen, welche zum Krankheitsbild «Krebs» führen können. Die 
Radiotherapie, angewendet alleine oder in Kombination mit anderen 
Behandlungsstrategien, zählt zu den Standardbehandlungen von Krebspatienten und 
hat zum Ziel Tumorzellen, mittels DNS Schädigungen, zu töten. Interessanterweise 
sondern bestrahlte Zellen viele Faktoren ins Tumormikromilieu ab, wo sie 
Signalkaskaden in auto- und parakriner Weise beeinflussen können. Durch die 
Radiotherapie werden folglich eine grosse Anzahl von Tumorzellen getötet, allerdings 
induziert sie ebenfalls eine vielschichtige Stressantwort, die mit dem optimalen 
Behandlungsresultat interferieren kann.  
Im Hinblick auf die Entwicklung neuer Angriffspunkten von Medikamenten, welche der 
Verbesserung der Radiotherapie dienen, fokussiert sich diese Masterarbeit auf die 
intra- und interzellulären Signalwege, die von der Metalloproteinase ADAM17 
beeinflusst werden. ADAM17 befindet sich an der äusseren Seite der Plasmamembran 
und ist für das Schneiden vieler Faktoren, welche in die Tumorprogression und 
Entzündung involviert sind, verantwortlich. In zahlreichen Krebsarten ist die ADAM17 
Expression erhöht, was wiederum mit einer schlechten Prognose korreliert. Ebenfalls 
konnten verschiedene vorhergehende Studien darlegen, dass das ADAM17 Protein 
eine Rolle in der Radiosensitivität hat.  
Ziel dieser Masterarbeit ist, den Effekt von einer durch shRNA-generieter ADAM17 
Herunterregulierung in zwei verschiedenen nicht-kleinzelligen Lungenkrebs Zelllinien 
zu analysieren, wobei der Fokus besonders auf deren Verhalten nach Bestrahlung 
gelegt wurde. Die resultierende Protein-Herunterregulierung führte gleichzeitig zu 
einer verringerten Enzymaktivität und darauffolgender reduzierter Liganden-
Absonderung. Zusätzlich haben ADAM17-defiziente Zellen eine Strahlendosis 
abhängige, reduzierte Wachstumsrate und klonogenes Überleben. Daraus kann 
geschlossen werden, dass das ADAM17 Protein in Mechanismen involviert ist, welche 
die Effizienz von ionisierender Bestrahlung beeinflussen.  
Im zweiten Teil dieser Arbeit wurde die Beteiligung von ADAM17 in intra- und 
interzellulärer Kommunikation, in Bezug auf Migration, analysiert. Erstaunlicherweise 
ist die Migration zu einem Sekretom voll mit ADAM17-Liganden erhöht gegenüber der 
Migration zu einem Sekretom mit spärlichen Mengen von ADAM17-Liganden. Diese 
Resultate deuten mindestens bezüglich der Migration auf eine starke Beteiligung von 
ADAM17 in der intra- und interzellulären Kommunikation hin.  
Summa summarum unterstreicht diese Arbeit die unbestreitbare Mitwirkung von 
ADAM17 in zellulärer Radioresistenz. Zusätzlich öffnet sie die Möglichkeit zur 
Identifizierung der intra- und interzellulären Regulationsmechanismen, welche durch 
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das ADAM17 Protein ermöglicht werden. Schliesslich unterstützt diese Arbeit ebenfalls 
die Evidenz für die Kombination der Radiotherapie mit einem potenten ADAM17 
Inhibitor, um bessere Behandlungsresultate zu erzielen
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1 INTRODUCTION 
1.1 HALLMARKS OF CANCER 
Cancer includes all different types of neoplastic growth, from benign cell accumulations 
to highly aggressive and invasive tumor sites. A tumor (Latin tumere: “to swell”) 
describes “a swelling of a part of the body, generally without inflammation, caused by 
an abnormal growth of tissue, whether benign or malignant” (oxford dictionary [1]). 
Each tumor is shaped in a dynamic and unique way, making it a challenge to determine 
the genetic and epigenetic alterations underlining the cause, maintenance and spread 
of malignant cells. Features allowing cells to become malignant cancer cells include 
traits that enable them to survive, proliferate and disseminate. Robert Weinberg and 
Douglas Hanahan described these different characteristics in 2000 in “The Hallmarks 
of Cancer”, concentrating the complexity of cancer into six main characteristics. Later, 
these hallmarks were completed by four more characteristics, resulting in now ten 
hallmarks of cancer (Figure 1). [2, 3] 
The ability of cancer cells to sustain chronic proliferation is a fundamental trait. In 
normal tissue, the production and release of growth promoting signals are carefully 
controlled, ensuring a homeostasis of cell number, maintenance of normal tissue 
architecture and function. Cancer cells, in contrast, can acquire sustained proliferative 
signaling by several alternative ways: producing growth factor ligands by themselves, 
stimulating normal cells to supply them with various growth factors, elevating the levels 
of receptor proteins thereby rendering the cells hyper-responsive to the limiting 
amounts of growth factor ligands or creating structural alterations in the receptor 
molecules to mediate ligand-independent firing. Defects in feedback mechanisms 
which ensure homeostatic regulation of the flux of signals can enhance proliferative 
signaling.  
Upregulating growth factor ligands is not enough, as cancer cells must also circumvent 
powerful signals that negatively regulate cell proliferation. Such signals often depend 
on tumor suppressor genes that govern the decisions of cells to proliferate or to 
activate senescence or apoptosis. Programmed cell death by apoptosis is a natural 
blockage to cancer development. Apoptosis can be attenuated in tumors that thrive in 
progressing to advanced states of malignancy, most commonly by the loss of the TP53 
tumor suppressor function.  
Unlimited growth seems to be restricted by the limited amount of successive cell 
growth-and-division cycles normal cells can pass through. In each cell cycle, the length 
of the telomeres (repetitive DNA at the end of chromosomes) is shortened and when 
the telomeres have lost their protective function, they will trigger crisis to prevent 
chromosomes from end-to-end fusions. Telomeres are centrally involved in the 
process of unlimited proliferation. Cancer cells express the specialized DNA 
polymerase telomerase which subsequently adds telomere repeat elements to the 
existing once, hence the chromosome is never threated from too short telomeres.[4] 
Telomerase activity provides resistance to senescence and crisis/apoptosis. 
To sustain the growing tumor mass with oxygen and nutrients, the “angiogenic switch” 
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is activated and stays on throughout tumor development to continually mount new 
vessels into the growing tumor.[5] The neovascularization is controlled by a complex 
signaling network involving the cancer cells and the stromal microenvironment.  
The stromal microenvironment is also an important mediator of invasion and 
metastasis. Invasion and metastasis are multistep processes marked by the 
downregulation of cytostatic factors and upregulation of molecules associated with 
migration. Due to the near impossible detection of metastasis and the possible spread 
to all kind of organs, invasion and metastasis are a great threat resulting in the most 
often cause of death. [3] 
But what allows the cancer cells to survive, proliferate and disseminate? Hanahan and 
Weinberg described, additionally to the six Hallmarks of cancer, the four enabling 
characteristics. The most prominent enabling characteristic is genomic instability in 
cancer cells, which includes rare genetic changes orchestrating hallmark capabilities. 
A second enabling characteristic involves the inflammatory state of tumor lesions. 
Inflammation supplies bioactive molecules (e.g. growth factors, survival factors, 
proangiogenic factors) to the tumor microenvironment. [6] The third describes the 
cancer cells ability to cope with the increased need of energy of the forming tumor by 
reprogramming the cellular energy metabolism. Most notably, cancer cells limit their 
energy metabolism largely to glycolysis even in the presence of oxygen. This 
reprogramming was first described by Otto Warburg and is thus called the “Warburg 
Figure 1. Ten Hallmarks of Cancer by Weinberg and Hanahan 
(2011) 
Weinberg and Hanahan described the 10 Hallmarks of Cancer. 
Figure adapted from [2]. 
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Effect”. [7] Last but not least, tumors manage to avoid detection by the immune system 
or limit the extent of killing by immune cells, and hence can continue to grow and 
spread.   
1.1.1 Tumor Microenvironment/Metastasis 
Metastases arise when cancer cells migrate and invade into distal healthy tissue. To 
acquire this migratory phenotype, cancer cells increase the expression of genes 
required for cell motility, which respond to cues from the microenvironment, ultimately 
triggering invasion.  
The tumor microenvironment (TME) consists of cancer associated fibroblasts (CAF), 
endothelial cells, inflammatory cells, extracellular matrix (ECM) and diffusible 
molecules (growth factors, cytokines). Cancer cells are in constant interaction with the 
TME and this crosstalk can promote tumor progression by conferring cancer cells with 
the ability to proliferate, migrate, invade and metastasize (Figure 2). Specialized 
intercellular junctional proteins maintain epithelial cell contact with neighboring cells, 
allowing the cancer cells to communicate with each other, either directly by cell-to-cell 
contact or indirectly in a paracrine fashion. The release of various inflammatory 
cytokines, growth factors and proteases forms a metastasis-permissive 
microenvironment. [8, 9] 
Figure 2: Metastasis is a multistep process relying on 
the communication between cancer cells and the 
tumor microenvironment 
The tumor microenvironment consists of many different cell 
types, collectively enabling tumor growth and progression. 
It evolves throughout cancer progression thereby enabling 
migration, invasion and metastatic growth. [2] 
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The epithelial-to-mesenchymal-transition (EMT) marks the beginning of the invasion 
process (of epithelial-derived cancers = carcinomas). First, cancer cells lose their cell-
cell adhesion structures, change their polarity and organization of their cytoskeleton 
and become isolated and motile.[10] At distant tissues, the cells can extravasate into 
the parenchyma, undergoing the mesenchymal to epithelial transition (MET) and form 
micrometastases. If the local microenvironment permits it, such micrometastases can 
colonize, forming metastases. Until now, it is not known whether carcinoma cells 
acquire the capability to invade by activation of parts of the EMT program, or whether 
alternative regulatory programs, such as a crosstalk between cancer cells and stromal 
cells, can also enable invasion capability. 
The complex signaling interactions between cancer cells and the surrounding 
nonmalignant stroma evolve throughout the multistep tumor development and 
represent one of the major challenges in cancer research. 
1.2 TREATMENT STRATEGIES FOR CANCER 
With increased understanding of the molecular mechanisms and characteristics of 
cancer, the focus of treatment has shifted from relatively general cytotoxic agents to 
selective, mechanism-orientated and personalized therapeutics. Prior to treatment and 
to personalize the treatment strategy, the stage, location within the body, the grade, 
the genetic background, the metastatic status and the general health status of the 
patient are assessed.  
The general treatment strategies are surgery, radiotherapy, chemotherapy, molecular 
target therapy, immunotherapy and the combination of those.  
1.2.1 Radiotherapy 
Radiotherapy uses ionizing radiation (IR) to kill cancer cells, mainly by causing DNA 
damage that eventually leads to cell death. 
Ionizing radiation is defined by the localized release of large amounts of energy. It can 
be classified as directly or indirectly ionizing. Protons and Electrons are directly 
ionizing: if the individual particles have sufficient amount of kinetic energy, they can 
disrupt the atomic structure of the absorber (in the cell the absorber may be proteins, 
lipids and the DNA molecule). This generates chemical and biological changes. 
Electromagnetic radiations (x- and γ-rays) are indirectly ionizing, meaning they do not 
produce chemical and biological damage themselves. X- and γ-rays transmit their 
energy when they pass through the absorber which subsequently produces fast-
moving, charged particles which then can produce damage.  
Additionally, the effects of x- or γ-rays can be subdivided into direct or indirect (Figure 
3). The direct action of x- or γ-rays lays in the absorbance in biological material, directly 
interacting with the critical targets of the cells. The target itself will be ionized or excited 
and subsequently initiate the chain of events leading to biological changes. 
Alternatively, ionizing radiation produces free radicals by interacting with atoms or 
molecules in the cell (mainly water). When a photon of x- or γ-rays interacts with a 
water molecule, the water molecule becomes ionized, becoming an ion radical (H2O•+) 
that is charged and has an unpaired electron. The ion radical reacts with another water 
molecule, forming the highly reactive hydroxyl radical OH• which can diffuse to a critical 
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target of the cell, causing biological damage. [11] 
The most important biological impairment of IR is DNA damage. Single-Strand Breaks 
(SSB) occur prevalently but are of little biological consequence because they can be 
repaired efficiently by repair mechanisms of the cell by using the other strand as 
template. A radiation induced DNA Double Strand Break (DSB) causes the disruption 
of chromatin into two pieces and yields a greater threat concerning cell killing, 
carcinogenesis and mutation. Cancer cells frequently have mutations in genes 
controlling the DNA damage response. This and their highly proliferative character 
make them especially susceptible to DNA damage induced by IR. [12]  
 
Radiation Therapy (RT) is used in ~50% of patients with solid tumors, either as primary 
strategy to target the tumor, as palliative treatment or in combination with other 
treatment modalities (surgery, chemotherapy or immunotherapy). It can be 
administered by an external beam from outside the body which points the high-energy 
rays to the location of the tumor (most common approach) or it can be administered as 
internal radiation (or Brachytherapy) from inside the body. Radiation is given in 
fractions, giving the normal, healthy cells time to repair the damage caused to the DNA 
and therefore reducing normal tissue toxicities to the body.[13] 
1.2.1.1 5 R’s of Radiotherapy 
In 1975, Rod Withers published a paper describing the “The 4 R’s of Radiotherapy”. 
This short list contained the mechanisms which are important in determining the 
response of a biological tissue to multiple doses of radiation: Repair, Reassortment, 
Repopulation and Reoxygenation. These 4 R’s are still of great importance, though 
they have been completed with a fifth R, Radiosensitivity. [14] In optimizing these key 
biological parameters, local tumor control can be improved, and normal tissue toxicity 
minimized.  
The first R, Repair, stands for the efficient repair of lesions such as DNA SSBs and 
Figure 3. Direct and Indirect Actions of Ionizing Radiation 
Ionizing radiation (X and γ-rays) can act directly on the DNA or indirectly by producing 
free radicals.  Figure adapted from [11] 
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DSBs. The radiation induced, sublethal damage can only be repaired in cells with intact 
DNA repair mechanisms. By administering the radiation dose in fractions, normal cells 
have enough time to repair the damaged DNA whereas cancer cell, with mostly 
mutated repair mechanisms, cannot. Persistent DNA DSBs can lead to mitotic 
catastrophe, and eventual cell death.  
The second R, Redistribution, stands for the fact that radiation sensitivity varies among 
the different cell cycle stages. Cells in M and late G2 phase are most sensitive to 
radiation whereas cells in late S phase are more resistant. This pattern of 
radiosensitivity correlates with the different mechanism of DNA repair active in different 
stages of the cell cycle. During late S phase, DNA DSBs are repaired by Homologous 
Recombination (HR) which is a high-fidelity repair mechanism using the homologous 
strand of the sister chromatid as a template. When no sister chromatid is available, for 
instance in M and G2 phase, Non-Homologous End Joining (NHEJ) is the primary 
repair mechanism. NHEJ is error prone, leading to chromosomal aberrations and 
accumulation of these aberrations can result in cell death. By having a highly 
proliferative character, cancer cells constantly go through the different phases of the 
cell cycle, eventually being in a sensitive phase when a fraction of radiation is applied.  
The third R, Repopulation, stands for the radiation-induced accelerated repopulation 
of tissue as cells try to fill the void created by dying cells.  
The fourth R, Reoxygenation, describes the benefit of letting parts of the tumor be re-
oxygenated between the fractions. Tumor cells grow at such a high rate without any 
hindrance, eventually coming to a point where not all cells of the tumor mass have 
access to oxygen and nutrient delivering blood vessels. Cells without sufficient oxygen 
do not cycle through the cell cycle stages, residing in the radiation-insensitive phase 
G1. By fractionating the giving dose, tumor cells at the edge are killed, allowing oxygen 
to diffuse to the previously blocked inner tumor cells, pushing them through the cell 
cycle and putting them eventually in a radiation-sensitive phase.  
The fifth R, Radiosensitivity, states that apart from Repair, Redistribution, 
Reoxygenation and Repopulation, the intrinsic radiosensitivity differs between different 
cell types. More sensitive cell types include stem cells, sperm and egg cells, intestinal 
cells and blood cells (virtually all actively dividing cells) and more resistant cells types 
include cells that do not divide, for example neurons or brain cells. [15] 
1.2.1.2 Unfavorable Effects of Radiation 
The ultimate goal of radiation therapy is to kill target cells, mostly by means of DNA 
damage that is beyond the repair capacity of cancer cells. Unfortunately, also non-
irradiated cells show various biological effects of IR, a phenomenon described as the 
radiation-induced bystander effect (RIBE).[16] RIBE is mediated by direct cell-cell 
contact (gap-junction mediated intercellular signaling) or by a range of soluble 
signaling molecules (e.g. TGF-β, TNF-α, IL-6) dispersing between distanced cells 
(Paracrine intercellular signaling).  
Several factors released upon RT (cytokines, growth factors, ROS), activate receptor-
mediated pathways and create a positively regulated loop capable of maintaining a 
permanent signaling between cells and the tumor microenvironment. This highly active 
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signaling network can create pathological conditions favorable for tumor invasiveness 
and cancer progression. [17-19] 
1.2.2 Chemotherapy 
Chemotherapy consists of drugs mainly interfering with the cells ability to divide 
properly. Chemotherapeutic agents can be divided into several subgroups: Alkylating 
Agents are cell-cycle unspecific and act directly on the DNA by causing DNA strand 
breaks. These result in abnormal base pairing, inhibition of cell division and eventual 
cell death. [20] Derived from certain types of plants, Plant Alkaloids are cell cycle 
specific by primarily acting during M phase, where they inhibit the formation of spindles 
and therefore interfere with the correct chromosome segregation. Antimetabolites are 
very similar to normal component of the cells and they compete with these normal 
components for the active site of an essential enzyme. Through that, they can impede 
for example the DNA (makes them cell cycle specific) and render the cell unable to 
divide. Another agent, also cell cycle specific, is the topoisomerase inhibitor which 
inhibits the DNA detangling enzyme topoisomerase, therefore repressing replication.  
Chemotherapeutic agents are not cancer type specific, but target in general the 
proliferative subset of cells in the body (Skin cells, hair cells, cells of the intestinal 
lining), leading to treatment-induced off-targets toxicities. Normally, chemotherapy is 
administered as a combination of different types of cytotoxic agents.[21] 
1.2.3 Surgery 
By practical thinking, a patient with a non-hematological cancer can be cured by 
removing the malignant cells by surgery. Indeed, many patients undergo surgery to 
excise the tumor, alone or with the whole organ affected. Unfortunately, tumors, also 
small ones, can spread to other sites of the body, forming metastases or the remaining, 
even so little, tumor cells can regrow to form another, maybe even more aggressive, 
tumor. This is the reason why surgery is often accompanied by other treatment 
strategies such as chemotherapy or radiation therapy.  
Being undeniably one of the most successful single modality, surgery has evolved over 
the years, also thanks to the rapid technical evolution, resulting in robots that can assist 
during the surgery (e.g. da Vinci Prostatectomy) and an extinction of surgery as a 
cancer treatment modality is very unlikely. [22] 
1.2.4 Molecular Targeted Therapy 
With the remarkable advances in the understanding of the molecular mechanisms 
underlying malignant progression of cancer, molecular targeted cancer therapy led to 
many clinical successes. Unfortunately, molecular targeted therapies are faced with 
many problems such as development of drug resistance, marginal response rate, and 
short-lived responses followed by disease progression.  
Molecular targeted therapy usually blocks the growth and spread of cancer by 
interfering with distinct molecules responsible for cancer progression (e.g. tyrosine 
kinase). In contrast to chemotherapy agents that interfere with standard cell 
mechanisms and molecules, targeted therapies work on molecular abnormalities 
specific for a cancer type and is consequently less harmful for non-malignant cells.  
Growth factor receptors and non-receptor signaling molecules represent the largest 
class of drivers for cancer cell development and agents targeting exactly such 
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molecules showed the initial success of targeted therapy, namely with trastuzumab 
targeting the HER2-RTK and imatinib targeting the non-receptor tyrosine kinase Bcr-
ABL. The most recent exciting success with molecular targeted therapy was achieved 
with the blockade of immune checkpoint molecules (CTLA-4, PD1 and PD-L1) and has 
led to explicit discussions about revisiting cancer immunotherapy.[23] 
1.3 NON-SMALL-CELL-LUNG-CANCER 
Lung Cancer is responsible, together with colorectal and prostate (men) or breast 
(woman), for the most commonly diagnosed cancer. In terms of cancer-related death, 
lung cancer climbs to the top of that list, being responsible for 27% of cancer-related 
deaths. [24] More than 85% of the newly diagnosed cases are classified as non-small-
cell lung cancer (NSCLC) for which the predicted 5-year survival rate is only at 15.9% 
- a number that has unfortunately only marginally improved during the last few 
decades.[25]  
NSCLS are subcategorized into adenocarcinoma, squamous cell carcinoma (sqCC) 
and large cell carcinoma. SqCC is a malignant epithelial tumor reflecting keratinization 
and/or intercellular bridges. Over 90% of SqCC occur in cigarette smokers. 
adenocarcinoma is a malignant epithelia tumor with glandular differentiation or mucin 
production and has surpassed SqCC as the most common histologic subtype of lung 
cancer. Most cases of Adenocarcinoma are seen in smokers, it however develops 
more frequently than any other type of lung cancer in non-smokers. Large cell 
carcinoma is an undifferentiated NSCLC lacking the cytologic and architectural 
features of small cell carcinoma and glandular or squamous differentiation.[26] 
The treatment of NSCLC has evolved over the past decade and early diagnosis and 
surgical treatment are important for optimal patient outcome. However, the majority of 
patients are diagnosed only at later, progressed stages and require multimodality 
therapy. The increased understanding of the molecular heterogeneity underlying 
cancer initiation and progression, as well as advances in standard of care, significant 
improvement in the management of patients with advanced stages of lung cancer have 
been made.[27] Nonetheless, the mortality rate is still very high. Pursuing further 
research on characterizing NSCLC and developing novel treatment strategies is 
therefore of utmost importance.   [28] 
1.4 ADAM17 
The surface-expressed disintegrin and metalloproteinase ADAM17 (also known as 
tumor necrosis factor α-converting enzyme, TACE) is found in most tissues, is 
constitutively expressed in various cells and plays important roles in divers 
physiological and pathophysiological processes. [29] It processes single-spanning 
membrane proteins such as cytokines, growth factors, receptors and chemokines. Up 
until now, over 80 substrates have been identified, most of which are implicated in 
cancer and inflammation. ADAM17 has become an attractive target for therapeutic 
intervention because it has been discovered that, despite its broad substrate profile, it 
is typically further activated in response to stimuli that drive disease states, for example 
tumor progression, tumor-induced angiogenesis and hypoxia-induced tumor cell 
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invasiveness. [30] The study of the shedding events orchestrated by ADAM17 
proposed novel mechanisms of resistance to popular cancer therapies. [31] 
1.4.1 Protein Structure 
ADAM17 consists of ~750 amino acids and its domain structure has a pro-domain, a 
metalloprotease domain, a disintegrin domain, a cysteine-rich domain, and EGF-like 
domain, a transmembrane domain, and a cytoplasmic tail (Figure 4). The pro-domain 
has a chaperon function and inhibits catalytic activity. The pro-protein convertase furin 
cleaves the protein and consequentially the catalytic domain is de-repressed. 
ADAM17’s activity can be regulated by several mechanisms including gene 
expression, intracytoplasmic and pericellular regulation, zymogen activation and 
inhibition by inhibitors. [32-35] 
1.4.2 ADAM17-mediated Signaling Pathways 
The best characterized function of catalytically active metalloproteases is protein 
ectodomain shedding, which allows membrane-tethered factors to participate in auto- 
and/or paracrine signaling. A cleaved substrate can bind to its receptor, initiating 
downstream signaling. On the other hand, a receptor can be cleaved from the cell 
membrane and thus ligand-initiated signaling is stopped. Furthermore, ectodomain 
shedding is an important element of intercellular communication (Figure 5). [36]  
ADAM17 is major convertase of ligands binding the Epidermal Growth Factor Receptor 
(EGFR)-related receptors such as TGF-α, Amphiregulin and Epiregulin. The EGF- 
receptor (ErbB1) is an important tyrosine kinase receptor whose downstream signaling 
regulates, among others, proliferation and migration and thus has crucial roles in 
development and cancer. [37] For example, the enhanced shedding of these ligands 
activates the ErbB receptors, also in distant cells. Aberrant ErbB receptor activity has 
been implicated in tumor development and progression.  
Additionally, ADAM17 cleaves cell adhesion molecules that contribute to the cells 
Figure 4. Structure and function of ADAM17 
ADAM17 consists of six different domains, each having a 
distinct function. After removal of the pro-domain, the catalytic 
domain becomes activated. Figure adapted from [34] 
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migratory and invasive capacity. For example, CD44, a binding molecule for 
hyaluronan, mediates migration and invasion of tumor cells and high expression and 
release of CD44 in the TME is correlated with an increased metastatic potential of 
tumor cells. Another adhesion molecule targeted by ADAM17, ALCAM (activated 
leucocyte adhesion molecule, CD166), is involved in several biological processes 
including hematopoiesis, immune response and migration and its expression and 
regulation may play a role in tumor progression. [29, 38] 
Beyond the shedding of growth factors and its impact on neoplastic growth, ADAM17 
is involved in the activation, recruitment and resolution of innate and adaptive immune 
responses. For example, Amphiregulin can induce proliferation and activation of 
regulatory T cells, thus also has an immune-suppressive function. [39] 
The ubiquitous signaling pathways ADAM17 is involved in, with unique cell and tissue 
specific effects, underline the rational to investigate mechanisms for controlling 
ADAM17 activity.  
 
Figure 5. ADAM17-mediated signaling 
Function of ADAM17 is regulated by phosphorylation of the 
cytoplasmatic tail by intercellular kinases. For ADAM17 
activation, Phosphatidylserine is transferred to the outer 
leaflet of the membrane. ADAM17 processes over 80 single-
spanning membrane proteins, including growth factors and 
cytokines that bind to receptors leading to activation of 
intracellular signaling pathways. [34]  
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1.4.3 ADAM17 in Cancer 
ADAM17’s involvement in pleiotropic events in tumorigenesis, including stimulation of 
proliferation and escape from immune surveillance (Figure 6), has led to studies 
identifying ADAM17’s response to different treatment modalities. For example, 
ADAM17 activity is increased in cells treated with chemotherapeutic agents 
(fluorouracil), resulting in growth factor shedding, growth factor receptor activation and 
drug resistance. [40] Recently, it has been proven that in response to ionizing radiation, 
the furin-mediated activation of ADAM17 is promoted in NSCLC cells with increased 
shedding of ADAM17 substrates, contributing to an IR-induced stress response in 
these cells. [41]  
ADAM17 overexpression has been linked to increased proliferation, invasiveness and 
poor prognosis in several different cancer types [42-44] which is why it has become an 
attractive therapeutic target. By inhibiting ADAM17 activity in tumors, proliferation and 
invasion can potentially be diminished and it may support immunosurveillance, all in 
all helping to control tumor progression and improving the treatment outcome. 
 
 
 
 
 
   
Figure 6. Multiple Processes are affected by ADAM17 
ADAM17 displays a wide array of actions, systemic or cell-
type specific. Focusing on cancer, ADAM17 influences eight 
processes which are actively involved in cancer progression. 
12 
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1.5 AIM 
Radiotherapy has been used to treat patients for almost a century. Its cytotoxic insult 
on the DNA is the main reason it has been used and extensively studied.[11, 45] 
Ionizing radiation also induces a multilayered stress response including auto- and 
paracrine factors that are released into the tumor microenvironment. These intra- and 
intercellular processes can co-determine treatment response and eventually treatment 
outcome. [18, 46] 
The family of matrix metalloproteases are important orchestrators of shedding proteins 
on the outer side of the cell membrane. They are important players of auto- and 
paracrine signaling within the primary tumor, the tumor microenvironment, secondary 
distal tumors and metastases, and therefore represent a promising target in the field 
of radiobiology. To date, only limited comprehensive analyses have been performed 
with regard to the role of an irradiation-regulated serum proteome (secretome), in 
particular to a specific sheddase of interest. [47] 
ADAM17, a disintegrin and metalloproteinase, drives pleiotropic pathways and 
increased ADAM17 expression is associated with aggressive progression of tumor 
growth and poor prognosis [31, 32, 39, 48]. Due to its broad spectrum of activity, 
ADAM17 represents an ideal target for combined treatment with IR. Previous results 
from our group identified ADAM17 as an important resistance mediator in response to 
IR. Using a potent ADAM17-inhibitor (TMI-005), radiosensitivity was increased. [41] 
These findings directed us to the goal to uncover the underlying molecular mechanisms 
of ADAM17 mediated radiation sensitization and its role in auto- and paracrine 
signaling and provide the baseline for my master thesis.   
Precisely, my master thesis aims to investigate two different aspects: 
a) Characterize the tumor cell’s response to IR upon ADAM17-
downregulation in vitro  
To study the underlying mechanism of ADAM17-mediated resistance, we generate 
inducible ADAM17-knockdown cells using short-hairpin RNA (shRNA). The decision to 
choose an inducible shRNA knockdown system over a complete gene knockout by 
CRISPR/Cas9 was based on the interest in the regulation of ADAM17 levels to control 
the secretome in response to irradiation rather than a complete gene knockout of 
ADAM17.  
We aim to validate and use the inducible shRNA system in order to identify biochemical 
and cell-biological mechanisms altered by the ADAM17 downregulation (e.g. protein 
level and activity). Furthermore, we will identify the efficacy of ADAM17-
downregulation to sensitize cells towards ionizing radiation.  
b) Quantitatively assess the ADAM17-dependent intercellular 
communication in response to IR  
ADAM17 is a highly active metalloproteinase with many different target substrates. 
Many substrates are known to play a key role in tumor development and progression. 
We hypothesize that ADAM17 ligands are actively involved in intra- and intercellular 
communication responsible for tumor behavior, such as migration.   
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Using a transwell migration assay, we will evaluate the paracrine effect of a secretome 
generated by ADAM17-proficient cells as compared to a secretome produced by 
ADAM17-knockdown cells.  
Together, these results will help us to uncover auto- and paracrine effects of ADAM17 
and underline the rational for combining IR with a potent ADAM17 inhibitor to improve 
treatment outcome.   
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2 MATERIALS AND METHODS 
2.1 METHODS 
2.1.1 Cell Culture 
The human non-small cell lung cancer (NSCLC) cell lines A549 and H358 were 
cultured in RPMI 1640 cell culture media supplemented with 10% (v/v) fetal calf serum, 
1% (v/v) penicillin–streptomycin, and 1% (v/v) GlutaMAX (Thermo Fisher) at 37°C in 
5% CO2. All cell culture media and supplements were obtained from Gibco (Life 
Technologies).  
Stable A549 and H358 cell lines established to express an ADAM17-targeting shRNA 
or a non-targeting control shRNA under the control of a doxycycline-inducible promoter 
were grown as indicated above. To induce shRNA expression, 500ng/ml Doxycycline 
(Dox) was added to the growth medium for at least 48h prior to initiation of the 
experiments.  
To maintain a cell line in culture, 80-90% confluent dished were depleted of medium, 
washed with PBS and incubated in 0.25% EDTA-Trypsin to detach adherent cells. 
Cells were resuspended in an appropriate amount of cell culture medium and reseeded 
in a diluted variant.  
2.1.2 Irradiation 
Irradiation was performed using an Xstrahl 200 kV X-Ray unit at 100 cGy/minute. 
(Gulmay, Suwanee GA).  
2.1.3 Proliferation Assay  
Cells were incubated with Doxycycline for 72h and sham or 5Gy irradiated. The 
proliferative activity of tumor cells was assessed in 96- well plates with the colorimetric 
AlamarBlue assay (Biosource International). Through metabolization within the cell, 
AlamarBlue is irreversibly reduced to the pinkish and highly red fluorescent resorufin. 
The change in absorbance is measured and indicates the relative proliferative activity. 
Exactly 4h prior measuring the absorbance, 10µl AlamarBlue was added to the 
corresponding wells. The absorbance was measured at 590nm and 630nm by the 
Tecan GENios spectrophotometer.  
2.1.4 Clonogenic Assay 
Clonogenic cell survival was determined by the ability of single cells to form colonies 
in vitro as described [49]. Dox-induced cells were irradiated with different doses of IR 
and allowed to form colonies for 10 days. For fixation of colonies, cell media was 
removed, cells were washed with PBS and incubated for 20min with methanol/acetic 
acid 3:1. After removal of methanol/acetic acid, plates were left to dry overnight at RT. 
Next day, colonies were stained with crystal violet for 30min. Staining solution was 
removed, and plates were washed in water and left to dry. For evaluation, manual 
colony counting was assisted by a colony counting device (Gallenkamp). The plating 
efficiency (PE) was calculated by dividing the number of colonies by the number of 
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cells seeded on the non-irradiated control plate. Survival fraction (SF) was calculated 
as follow: 𝑆𝐹 =
𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝐶𝑒𝑙𝑙𝑠 𝑆𝑒𝑒𝑑𝑒𝑑
𝑃𝐸
 
2.1.5 TACE Activity Assay 
ADAM17 activity was analyzed with the InnozymeTM TACE activity kit (Merck, 
CBA042). Procedure was performed as instructed by the company. In brief, Dox-
induced cells were sham or 5Gy irradiated, and at different time points after irradiation, 
cells were harvested in CytobusterTM Protein Extraction Reagent. After normalization 
of the protein concentration (250ng/ul), samples (and control) were loaded on the 
precoated 96-well plate and incubated for 1h at RT with gentle shaking. Following a 
wash step, TACE substrate was added and the sealed plate was incubated 4-5h at 
37°C with gentle shaking. Fluorescence was measured at an excitation wavelength of 
~324nm and an emission wavelength of ~405nm.   
2.1.6 Western Blotting 
Samples were prepared by scraping them off in sodium dodecyl sulfate (SDS) sample 
buffer and heating for 5min at 95°C (Thermomixer compact, Eppendorf). Protein 
concentration was measured (NanoDrop 1000 Spectrophotometer, Thermo Scientific), 
normalized to ~ 1mg/ml and stored at -20°C.  
All samples were analyzed using SDS-polyacrylamide gel electrophoresis (PAGE). 
Usually, a running gel with a final concentration of 7.5% of acrylamide was prepared 
(see Table 1 for detailed description). 50 µg of samples were loaded into the 
corresponding wells and a current of 50mA was applied. The gel was the blotted onto 
a polyvinylidene fluoride (PDVF) membrane at 60V for 1h. The PVDF membrane was 
blocked with 5% blotting-grade blocker milk powder in TBS-Tween20 0.1% buffer for 
30min at RT. The membrane was probed with the primary antibodies (see Table 5) 
over night at 4°C with rotation at 200 RPM. Next day, the membrane was washed 3x 
for 10min with TBS-T buffer. The HRP-conjugated secondary antibody was diluted in 
5% milk (see Table 2) and incubated shaking for 1h at RT. The membrane was washed 
3x with TBS-T before the antibody was detected by chemiluminescence with the Vilber 
Lourmat Fusion FX Detector. 
Table 1. Tris-Glycine SDS-Polyacrylamide Gel Composition 
 Running Gel (7.5%) Stacking Gel 
ddH20 (ml) 7.5 3.01 
1.5M Tris pH 8.8 (ml) 3.75 - 
0.5M Tris pH 6.8 (ml) - 1.25 
30% acrylamide (37.5:1) (ml) 3.75 0.65 
10% APS (μl) 50 25 
TEMED (μl) 10 5 
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Table 2. Primary and Secondary Antibodies used for Western Blotting 
Antibody Supplier Species Dilution 
Primary Antibodies 
Anti-β-actin Sigma Aldrich Mouse 1:1000 
Anti-ADAM17 Cell Signaling Rabbit 1:1000 
Secondary Antibodies 
Anti-Mouse GE Healthcare Sheep 1:5000 
Anti-Rabbit Santa Cruz Mouse 1:7500 
 
2.1.7 Enzyme-Linked Immunosorbent Assay (ELISA) 
Cells were seeded in 6-well plate and allowed to attach for at least 12h. Medium was 
replaced with fresh RPMI (full) prior to irradiation. Plates were incubated at 37°C, 5% 
CO2, for 24h. Thereafter, medium was harvested and filtered through a 0.45 μm filter 
and cells were counted with a Neubauer Chamber. To measure Amphiregulin 
concentration in media, manufacturer’s protocol was followed (Duoset® Human 
Amphiregulin, DY262, R&D Systems). In brief, capture antibody was diluted to working 
concentration in PBS, added to 96-well plate and incubated overnight at 37°C, 5% 
CO2. Next day, plate was washed and blocked for 1h with Reagent Diluent at RT. 
Following a wash step, standards and sampled were added in triplicates and the sealed 
plate incubated for 2h at RT. Following another wash step, detection antibody was 
added, and the sealed plate was incubated for 2h at RT. Following a wash step, the 
streptavidin horse-radish peroxidase (HRP) and incubated for 20min at RT in the dark. 
Substrate A and B (1:1) were added and plate was incubated for 20min at RT in the 
dark. Stop solution was added and the absorbance was measured at 450nm with a 
wavelength correction at 540nm (Ultra Microplate Reader EL 808, Bio-Tek 
Instruments, Inc., Switzerland) 
 
2.1.8 Flow Cytometry 
A population of cells was prepared for flow cytometry by trypsinizing and filtering using 
standard protocol. Data were analyzed with FlowJo software (Ashland, OR). Cellular 
debris and dead cells were excluded by their light-scattering characteristics. 
Transduced A549 cells were gated according to intrinsic GFP or RFP expression as 
measured by a Becton Dickinson FACS LSRFortessa.  
 
2.1.9 Transwell Assay 
Transwell inserts (6.5 mm, 8um pores, Costar) were used to analyze the paracrine 
effect of ADAM17-secretome on A549 cell migration. Briefly, 1x105 A549 cells 
(control/knockdown) were plated into the lower chamber of the transwell containing 
1000μl complete RPMI medium and allowed to attach for a minimum of 12h. 
Thereafter, the medium was replaced with 1000μl RPMI supplemented with 1% (v/v) 
FBS, 1% P/S and 1% GlutaMax and the plate was sham or 5Gy irradiated and cultured 
for additional 6h. Next, 3x104 A549 cells in 100μl RMPI medium (1% FBS) were seeded 
into the upper chamber of the transwell inserts. The coculture was maintained at 37°C 
in 5% CO2 for 24h. For quantification, cells from the upper side of the insert were 
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scraped away with a cotton swap and inserts were then fixed in Methanol/Acetic Acid 
(75%/25%, v/v), dried and then stained with DAPI. Fluorescent microscopy pictures 
were taken (Axiovert 40 CFL, Zeiss with AxioCam MRc) and the migrated cells were 
counted manually.  
In this set-up, either cell type (upper well/lower well) can be treated independently from 
the other, but the two cell types will be able to communicate via the shared cell medium 
(Figure 9). Migration of cells through the PET membrane (8μm) can be stimulated by 
various factors that are produced by cells residing in the lower compartment. For the 
current study, either cell type’s secretome (control/knockdown) could be placed in the 
lower compartment and all cells (migrating/secretome producing) could be differentially 
irradiated (Figure 9 A-D). 
 
2.1.10 Production of stable cell lines 
 
2.1.10.1 Lentiviral Plasmid, shRNA Sequences and Vector Map 
The plasmid vector pRSITPRP-U6Tet-sh-PGK-TetRep-2A-TagRFP-2A-Puro (Figure 
7) was used to produce lentivirus for transduction of cell lines with inducible short-
hairpin-RNA mediated downregulation of ADAM17. The vector contains the PGK 
promoter driving expression of a Tet repressor (TetR), red fluorescent protein (RFP) 
and puromycin resistance and the inducible short hairpin RNA (shRNA, (Table 3)) is 
driven by the U6-Tet promoter sequences. This Tet-On system initiates the 
transcription and processing of the shRNA by addition of doxycycline and thus an 
expressional downregulation of the target protein (Figure 8).[50, 51] 
Table 3. shRNA nucleotide sequences 
Name Sequence 
shADAM17_NonTarget CAACAAGATGAAGAGCACCAA 
shADAM17.2 GATCATCGCTTCTACAGATAC 
shADAM17.3 CCTGGTTACAACTCATGAATT 
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2.1.10.2 Transformation of JM109 Competent E. coli Cells 
The JM109 competent E. coli cells (Single-Use JM109 Competent Cells, >108cfu/µg, 
Promega) were thawed on ice. To 90 µL of cells, 50 ng of plasmid in a volume of 10 
µL was added giving a total volume of 100 µL. The cells were incubated on ice for 30 
min, 45 sec at 42°C (Heat Shock) and then 2 min on ice again. 900 µL of prewarmed 
lysogeny broth (LB) media was added and incubated shaking at 37°C for 1 h. 
Thereafter, the bacteria were streaked on LB-agar selection plates (containing the 
antibiotic ampicillin, 100ng/mL). The plates were incubated over night at 37°C. The 
next day, one colony of transformed E. coli cells was picked and incubated in 3 mL LB 
media with ampicillin (100ng/mL) overnight at 37°C with shaking. The 3 mL cultures 
were transferred to 250 mL LB media with ampicillin (100ng/ml) and incubated with 
shaking at 37°C overnight. 
Figure 7. Vector-Map: pRSITPRP-U6Tet-sh-PGK-TetRep-2A-TagRFP-2A-Puro 
(8887bp) 
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2.1.10.3 Plasmid Amplification and Purification 
Plasmid purification was performed following the manufacturer’s protocol and using 
the HiSpeed® Plasmid Midi Kit (25) (Qiagen, Ref. 12643). 
 
2.1.10.4 Transfection of HEK293T Cells and Production of Lentiviral Particles 
HEK293T cells (human embryonic kidney 293 cells expressing the large tumor (T-) 
antigen from the SV40 virus) were transfected with the plasmid to generate lentiviral 
particle for later transfection of NSCLC cell lines. The manufacturer’s protocol 
(Cellecta: Packaging, Titering and Transduction of Lentiviral Constructs, 2015) was 
Figure 8. Tet-On System 
The Tet-On system allows the regulation of a gene of interest (G.O.I) by administration of 
tetracycline (or its derivatives like Doxycycline). This quantitative and temporal control of 
gene expression by an exogenous effector molecule reduces adverse effects and improves 
the safety of gene therapy.   
The Tet-On system is based on the reverse Tet-Repressor protein (Tet-On 3G Protein) and 
tet operator (PTRE3G) DNA elements. The Tet-On 3G Protein does not bind the PTRE3G in the 
absence of the effector (Doxycycline) (Fig. A). Binding of Doxycycline triggers a 
conformational switch in Tet-On 3G Protein which allows PTRE3G binding (Fig. B). The 
subsequent activation of the promoter drives expression of the downstream positioned gene 
(G.O.I).  
An ideal Tet-On system has low background activity in the absence and high activity in the 
presence of doxycycline. (Figure adapted from [50])  
A) 
B) 
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followed. In brief, the day before the transfection, 4 x 106 HEK cells were plated in a 
75 cm2 flasks and incubated over night at 37°C to have them at ~70% confluency the 
next day. For each lentiviral construct, 20 µl (to a final concentration of 10 µg/mL) of 
the ready-to-use packaging plasmid mix was mixed with 4 µL (to a final concentration 
of 2 µg/mL) of the plasmid. 1 mL of Opti-MEM media was added and incubated at RT 
for 15 min. 30 µl lipofectamine was mixed with 1 mL Opti-MEM media. 1 ml of the 
lipofectamine mix was added to the plasmid mixture and incubated at RT for 15 min. 2 
mL of the plasmid/lipofectamine mix was added to each 75 cm2 flask. The flasks were 
incubated at 37°C for overnight. The media was changed to fresh DMEM the next 
morning and cells were incubated at 37°C until the next day evening. The virus 
containing media was collected, spun down and the supernatant was filtered through 
a 0.45 µm PES low protein binding filter.  
2.1.10.5 Transduction of New Target Cells 
Target cells were seeded at 2.4 x 106 in a 75cm2 flask. When cells were around 80% 
confluent, 7ml of RPMI was mixed with 7ml of viral supernatant and 1.5 µl of polybrene 
(5µg/ml) and added to target cells. Flasks were incubated over night at 37°C. Next day 
the medium was removed and replaced by fresh RPMI medium and incubated 24h. 
Then, the medium was changed to RPMI containing 1ug/ml puromycin, to select for 
cells that successfully integrated the transgene. Cells were selected over a week 
(medium change every second day) and successful transduction was controlled by 
checking the GFP/RFP signal under a fluorescence microscope (Axiovert 40 CFL, 
ZEISS with AxioCam MRc). 
 
2.1.11 Statistical Analysis 
Statistical analysis was performed with GraphPad Prism 7.04. Data is represented as mean ± 
standard deviation of the mean (SEM). Significance was measured by unpaired student t test. 
P ≤ 0.05 was considered significant.  
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2.2 CELL LINES 
Table 4. Cell lines [52] 
Cell line Tissue Mutation 
  EGFR KRAS TP53 status 
A549 Human NSCLC wt mut wt 
H358 Human NSCLC wt mut mut 
HEK 293 T Human embryonic kidney cells 
(transformed with large T antigen) 
   
 
2.3 BUFFERS AND SOLUTIONS 
Table 5. Buffers and Solutions 
10 % APS 100mg/ml APS in ddH20 
Acrylamide solution 30 % 29.2g/l Acrylamide, 0.8g/l Bis-Acrylamide in 
ddH20 
Running Gel buffer 1.5M Tris, 0.1% SDS in ddH20, pH 8.8 
SDS running Buffer 0.3% Tris, 1.44% Glycine, 0.15% SDS 
SDS-sample buffer 125mM Tris, 4% SDS, 20% Glycerol in 
ddH20, pH 6.8 
Stacking Gel buffer 0.5M Tris, 0.1% SDS in ddH20, pH 6.8 
TBS-T 0.1M Tris, 150nM NaCl, 0.1% Tween-20 in 
ddH20, pH 8.0 
Transfer Buffer 100nM Tris, 192nM Glycine, 10% methanol 
 
2.4 CHEMICALS 
Table 6. Chemicals 
0.5 % Trypsin-EDTA 10x Gibco by Life 
Technologies 
2-mercaptoethanol Sigma - Aldrich 
Acetic Acid (glacial) 100 % Emsure®, Merck 
Acrylamide  Sigma 
Agarose Sigma 
Ampicillin Sodium Salt Sigma 
APS Ammonium Persulfate BioRad 
Bis-Acrylamide BioRad 
Blotting-Grade Blocker (Milk Powder) BioRad 
Boric Acid Fluka 
BSA (Bovine Serum Albumin) Sigma 
Coomassie Brilliant Blue Sigma 
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Crystal Violet Merck 
Custom Lentiviral shRNA Constructs (Plasmids) Cellecta 
CytobusterTM Protein Extraction Reagent Millipore, Novagen®, 
Merck 
DAPI Sigma - Aldrich 
Dimethyl sulfoxide (DMSO) Sigma - Aldrich 
DMEM Media Gibco by Life 
Technologies 
Doxycycline (Dox) Sigma 
ECLTM Anti-Mouse IgG Horseradish Peroxidase linked 
whole Antibody (from sheep) 
GE Healthcare 
ECLTM Anti-Rabbit IgG Horseradish Peroxidase linked 
F(ab)2 fragment (from donkey) 
GE Healthcare 
ECLTM Western Blotting Detection Agents AmershamTM, GE 
Healthcare 
Ethanol (EtOH) Merck 
FCS (Fetal calf serum) Gibco by Life 
Technologies 
Gelred (1000x) Biotium 
Glycerol Sigma 
LB Agar Powder, Lennox L Agar Invitrogen 
L-glutamine 200 mM (100x) Gibco by Life 
Technologies 
Lipofectamine 2000 Invitrogen 
Methanol (MeOH) Morphisto 
Monoclonal mouse anti-β-Actin Sigma Aldrich (#A5441) 
Opti-MEM Gibco by Life 
Technologies 
PBS pH 7.2 Kantonsapotheke Zürich 
Pen Strep (Penicillin/Streptomycin) Gibco by Life 
Technologies 
Polybrene Sigma Aldrich 
Polyclonal rabbit anti-ADAM17 Calbiochem (#PC491) 
Polyclonal rabbit anti-Akt Cell Signaling Technology 
(#9272) 
Potassium Chloride (KCl)  Fluka Biochemika 
Puromycin Dihydrochloride Sigma 
Ready-to-use-packaging Plasmid Mix Cellecta 
RPMI 1640 Media Gibco by Life 
Technologies 
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sodium dodecyl sulfate (SDS) Sigma 
Sodium Chloride (NaCl)  Sigma-Aldrich 
Tetramethylethylenamidin (TEMED) BioRad 
Trizma® base Sigma 
Tween® 20 Sigma 
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3 RESULTS 
3.1 LENTIVIRAL PLASMID AMPLIFICATION AND TRANSDUCTION OF NEW CELL 
LINES 
The addition of drugs inhibiting ADAM17 activity strongly enhanced the efficacy of IR 
in in vitro and in vivo studies as published by Sharma et al. [41]. To study the underlying 
mechanisms of ADAM17-mediated radioresistance, a lentiviral plasmid system was 
used to generate new doxycycline-inducible ADAM17-knockdown NSCLC cell lines.  
In this project, the two NSCLC cell lines A549 and H358 were transduced with the 
lentiviral particles. For each cell line, three different constructs, containing a different 
shRNA, were used: a non-targeting short hairpin (referred to as shNT or control), and 
two different short hairpins targeting ADAM17 (referred to as shADAM17.2/shA17.2 
and shADAM17.3/shA17.3). (see Table 3 for sequences) 
Cells were selected with puromycin containing medium and subsequently, A549 cells 
were analyzed by flow cytometry to verify the expression of GFP (shNT) or RFP 
(shADAM17). Flow cytometry scatter blots show that approximately 90% of A549 cells 
containing the non-target shRNA express the green fluorescent protein (Figure 10A) 
and approximately 90% of A549 cells containing the ADAM17-targeting shRNA 
(shADAM17.2 resp. shADAM17.3) express the red fluorescent protein (Figure 10 B+C) 
 
 
3.2 THE INDUCTION OF ADAM17-DIRECTED SHRNA REDUCES ADAM17 
PROTEIN LEVEL AND ACTIVITY 
After the successful transduction and selection of the new stable cell lines, the 
efficiency of the Tet-On System to downregulate ADAM17 was tested and analyzed by 
Western blot.  
Figure 10. Transduced A549 cells stably express the inserted vector as determined by 
GFP/RFP expression 
(A) Flow Cytometry scatter plot analysis showing GFP-expressing A549 cells containing the 
shNT. (B)+(C)   Flow Cytometry scatter plot analysis showing RFP-expressing A549 cells 
containing the ADAM17 targeting shRNAs (shADAM17.2 (B) resp. shADAM17.3 (C)).  
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In doxycycline-untreated cells (-), no differences in ADAM17 protein level were 
observed between the control cells and the cells harboring the shADAM17 constructs 
in cell lines A549 and H358. After adding doxycycline to the cells (+), protein levels of 
ADAM17 were decreased in cells transduced with shADAM17.2 and shADAM17.3 
constructs. While the two constructs showed similar knockdown efficiency in H358 
(Figure 11B), the shADAM17.2 was more efficient compared to shADAM17.3 in A549 
cells (Figure 11A). Protein levels in doxycycline-treated cells containing the non-
targeting shRNA were unaffected. (Figure 11 A+B) 
The activity of ADAM17 protease in doxycycline-treated A549 and H358 cells was 
assessed with a protease activity assay. In line with protein downregulation, protease 
activity was reduced in A549 and H358 cells harboring the shADAM17 constructs 
relative to control cells. The activity reduced to approximately 30% in A549 (both 
shADAM17 constructs, Figure 11C) and to approximately 40% (shADAM17.2, Figure 
11D, light red) or 80% (shADAM17.3, Figure 11D, dark red) in H358 cells relative to 
corresponding control cells. The activity reduction is still apparent following irradiation 
(5Gy), being at approx. 50% in A549 cells (both constructs, Figure 11E) and at 10% 
(shADAM17.2, Figure 11F, light red) resp. 50% (shADAM17.3, Figure 11F, dark red) 
in H358 cells relative to the corresponding control cells. 
 
Figure 11: Tet-On System results in decreased ADAM17 protein levels and activity 
(A) + (B) A549 or H358 cells were not induced (-) or induced (+) with Dox (500ng/ml) 72h 
prior to lysis. Whole cell lysates were loaded onto a 7.5% gel and subjected to analysis by 
immunoblotting using the indicated antibodies. (C) + (D) A549 or H358 cells were induced with 
Dox (500ng/ml) 72h prior to sham or 5Gy irradiation. 24h thereafter, relative ADAM17 enzyme 
activity was determined. Data displayed as relative mean ± SEM and analyzed with unpaired 
student t test. Significance level p<0.05. 
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3.3 ADAM17 ENZYME ACTIVITY INCREASES UPON IR 
Posttranslational modifications, and not increased protein expression, result in higher 
ADAM17 enzyme activity following irradiation.[41] In A549 control cells, the ADAM17 
protease activity increased in a time dependent manner, reaching its maximum with 
an approximately 2.5-fold increase 24h after irradiation (Figure 12A). Neither in the 
cells harboring the shADAM17.2 construct (Figure 12B) nor in cells with the 
shADAM17.3 construct (Figure 12C), a time dependent increase in protein activity 
could be observed. In H358 control cells, the ADAM17 protease activity increased 
concomitantly over time after irradiation, reaching its maximum with an approximately 
1.5-fold increase 6h after irradiation. After 6h, the activity decreased to basal level 
(Figure 12D). In contrast, the cells harboring the shRNA constructs targeting ADAM17 
(shADAM17.2 resp. shADAM17.3) did not show an increase in ADAM17 protease 
activity following irradiation (Figure 12E+F). 
 
3.4 ADAM17 DOWNREGULATION RESULTS IN DECREASED LIGAND SHEDDING 
The semi-quantitative large-scale secretome analysis performed by Sharma et al. 
showed increased secretion of several substrates of ADAM17, in particular 
Amphiregulin and ALCAM. [41] 
The amounts of Amphiregulin in culture media of non-irradiated or irradiated A549 
shNT resp. shADAM17 cells were measured by an Amphiregulin-directed ELISA. 
Figure 12. ADAM17 activity increases over time after irradiation 
(A) - (F) Dox-induced A549 or H358 cells were irradiated with 5Gy. ADAM17 activity 
was determined before and at different timepoints after irradiation. Data displayed as 
relative mean ± SEM and analyzed with student t test. Significance level p<0.05. 
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There was significantly less secreted Amphiregulin in the supernatant of ADAM17-
knockdown cells compared to control cells (Figure 13A). 
However, when the Amphiregulin levels in supernatant of non-irradiated cells were 
compared to supernatant of irradiated cells, a significant increase was seen not only 
in the shNT control cells, but also in the shADAM17 cells, albeit it started from a lower 
baseline level (Figure 13B). 
 
3.5 ADAM17 DEPLETION SENSITIZES CELLS TOWARDS IONIZING RADIATION 
The previous results demonstrated that downregulation of ADAM17 by shRNA 
decreases the protein level, the total protein activity and the level of secreted ligands. 
As a functional readout and to study whether reduced ADAM17 protein activity 
sensitizes cells to IR, proliferation and clonogenic assays were performed.  
A549 shNT cells displayed a higher proliferative activity compared to cells containing 
the shADAM17.2 but not to cells containing the shADAM17.3. The difference in 
proliferative activity was amplified in a dose-dependent way if cells were subjected to 
irradiation (Figure 14A). Depletion of ADAM17 in H358 cells had no effect on the basal 
proliferative activity, as there was no difference detectable compared to control H358 
cells. Following irradiation with 3Gy or 6Gy, ADAM17-depletion resulted in decreased 
proliferative activity also in H358 shADAM17 cells compared to control cells (Figure 
14B). 
In the clonogenic assay performed with the A549 control/knockdown cells, the survival 
fractions are represented as a function of dose.  A549 shADAM17 cells had lower 
clonogenic survival compared to control cells when treated with increasing doses of 
ionizing radiation above 4Gy (Figure 14C). 
 
Figure 13. The secretion of the ADAM17 substrate Amphiregulin is enhanced following 
IR 
(A)+(B) A549 cells were sham or 5Gy irradiated and 24h thereafter the supernatant was 
collected. The amount Amphiregulin in the supernatant of A549 control resp. knockdown cells 
was measured by Enzyme-Linked Immunosorbent Assay (ELISA). Data displayed as mean ± 
SEM and analyzed with unpaired t test. Significance level p<0.05. 
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3.6 ADAM17-CLEAVED FACTORS ARE INVOLVED IN INTERCELLULAR 
COMMUNICATION 
The previous results demonstrated that ADAM17s enzyme activity is upregulated in 
response to IR, leading to more secreted substrates. In addition, cells with normal 
ADAM17 protein level are more resistant to ionizing radiation compared to cells with 
decreased ADAM17 protein levels.  
Multiple studies have already assessed the effect of ADAM17 on migration and 
concluded that ADAM17 knockdown cells show decreased migration and invasion 
capabilities.[30, 53] To test if ADAM17 is involved in intra- and intercellular 
communication and influences the cell behavior by autocrine and paracrine signaling, 
respectively, a transwell migration assay was performed. In line with former studies, 
the A549 cells harboring the shADAM17 construct used in this study showed 
decreased migration capabilities towards complete medium compared to control cells. 
(Figure 15A-C) 
 
 
Figure 14. ADAM17 depletion sensitized cells towards IR resulting in lower proliferative 
activity and decreased clonogenicity 
(A) + (B) Doxycycline induced cells (A549 and H358) were 0 Gy, 3 Gy or 6 Gy irradiated and 
72h later their proliferative activity was measured using the AlamarBlue Cell Viability Reagent. Data 
displayed as mean ± SEM and analyzed with unpaired t test. (C)   A549 cells were irradiated at 
increasing doses (0, 2, 4, 6 Gray) and following their capacity to form colonies was analyzed. Data 
displayed as mean ± SEM and analyzed with student t test. *p<0.05, **p<0.005, ***p<0.001   
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Next, the migration capacity of A549 shNT cells towards an ADAM17-dependent 
secretome was studied. 
A549 shNT cells could migrate towards a secretome produced either by A549 shNT or 
shADAM17 cells (Figure 9A+B, left) Interestingly, A549 shNT cells migrated better 
towards a secretome produced by control cells than by A549 shADAM17 (150.5±30.5 
cells/field versus 94±20.8 resp. 62± 22 cells/field, Figure 16A-C, G). 
Additionally, it was evaluated whether the increase of shed ligands in the secretome 
upon irradiation of A549 shNT or shADAM17 cells (as demonstrated in Figure 13) can 
amplify the difference between the migration towards secretome of shNT or 
shADAM17 cells respectively. For this, shNT cells could migrate towards a secretome 
coming from irradiated (5Gy) A549 shNT or shADAM17 cells (Figure 9A+B, right). 
Similar to the non-irradiated secretome, the A549 shNT cells migrated likewise less 
towards the secretome of A549 shADAM17 cells compared to secretome of A549 shNT 
cells (148.5±85.2 versus 132±12 resp. 72±16.4), although no further increase in the 
differential migration was observed (p>0.05). (Figure 16D-F, H).  
The migration behavior of non-irradiated cells differs from irradiated cells. [9, 54] 
Therefore, the differential migration of irradiated cells was assessed, to see if the same 
pattern of migration as in non-irradiated cells can be observed. Irradiated (5Gy) A549 
shNT cells could migrate towards a secretome coming from either non-irradiated or 
irradiated shNT or shADAM17 A549 cells (Figure 9C+D). 
Irradiated shNT cells migrated less towards the secretome of ADAM17-knockdown 
cells compared to secretome of shNT cells (117.2±12.4 versus 90.5±11.8 resp. 
57.5±25.2, Figure 17A-C, G) and irradiation of the secretome producing cells did not 
change the differential migration pattern (163±34 versus 72.5±31.2 resp. 80±28.6, 
Figure 17D-F, H). Of note is however the almost 1.4-fold increase in migration 
(117±12.4 versus 163±34, p=0.01) towards a secretome produced by irradiated shNT 
cells as compared to secretome of non-irradiated shNT cells (Figure 17A+D, G+H 
black bar). 
Figure 15. ADAM17 downregulation reduces migration capacity of A549 cells 
(A) + (B) A549 shNT or shADAM17.2 could migrate towards complete medium. After 24h, 
cells were fixed, stained with DAPI and analyzed under the microscope.  Representative 
microscopy pictures show migration of A549 shNT cells (A) and A549 shA17.2 cells (B). 
(C) For each condition, two separate membranes (n=2) were analyzed and combined data 
is represented in the bar graph. Data displayed as mean ± SEM and analyzed with student 
t test. Significance level p<0.05 
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Figure 16. A549 shNT cells migrate significantly less 
towards the secretome of ADAM17-knockdown cells 
(A)-(C)  shNT A549 cells could migrate towards secretome 
of non-irradiated control (A) resp. ADAM17-knockdown 
cells (B+C). (D)-(F) shNT A549 cells could migrate towards 
secretome of irradiated control (D) resp. ADAM17-
knockdown cells (E+F). (G)+(H) For each condition, two 
separate membranes (n=2) were analyzed and combined 
data is represented in the bar graph. (G) Data obtained 
from migration towards non-irradiated secretome (A-C). (H) 
Data obtained from migration towards irradiated secretome 
(D-E). Data displayed as mean ± SEM and analyzed with 
student t test. Significance level p<0.05 
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Figure 17. Irradiated A549 shNT cells migrate 
significantly less towards the secretome of ADAM17-
knockdown cells 
(A)-(C) Irradiated shNT A549 cells could migrate towards 
secretome of non-irradiated control (A) or ADAM17-
knockdown cells (B+C). (D)-(F) Irradiated shNT A549 cells 
could migrate towards secretome of irradiated control (D) 
or ADAM17-knockdown cells (E+F). (G)+(H) For each 
condition, two separate membranes (n=2) were analyzed 
and combined data is represented in the bar graph. (G) 
Data obtained from migration towards non-irradiated 
secretome (A-C). (H) Data obtained from migration towards 
irradiated secretome (D-E). Data displayed as mean ± SEM 
and analyzed with student t test. Significance level p<0.05 
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4 DISCUSSION 
Cancer is a leading cause of death worldwide.[55] Albeit being discovered over a 
century ago, radiotherapy is still a mainstay of current cancer therapy. Ionizing 
radiation is used as a standard treatment in most patients with solid tumors, either 
alone or in combination with chemotherapy, targeted therapy or more recently with 
immunotherapy. Biological factors that can influence treatment outcome include: 1) 
intrinsic radioresistance of cancer cells, 2) repopulation capacity of surviving cancer 
cells and 3) degree of hypoxia in the tissue environment. [46] 
Over the years, traditional RT has evolved. Newer technologies and combination with 
other treatment modalities have increased progression free survival and tumor control. 
Nonetheless, radiation therapy results in unwanted side-effects that could potentially 
harm the patient and therefore make the therapy unfavorable. Understanding the 
molecular mechanisms upon IR are therefore of utmost importance. 
Ionizing radiation aims to cause DNA damage exceeding the repair capacity of cancer 
cells and this cytotoxic effect on DNA level has been widely studied. [11, 12, 45] The 
effect of IR on the tumor microenvironment (TME) and how this can potentially 
influence treatment outcome is still under investigation. IR induces the secretion of 
various soluble factors which take part in communication between cells and the TME. 
This signaling is critical for tissue homeostasis and tumor growth.[16] Deciphering the 
role of this irradiation-regulated serum proteome, in particular when related to a specific 
sheddase of interest, as discussed in this project, will help to pave the way towards a 
combined treatment modality. [9, 18] 
 
ADAM17 is a membrane-associated metalloprotease and actively engaged in 
proteolytic shedding of membrane-bound proteins. ADAM17 is one of the matrix 
metalloproteases shown to be upregulated in response to IR and its overexpression is 
associated with aggressive tumor progression and poor prognoses. [32, 43, 48] The 
quantitative large scale secretome analysis of Sharma et al showed that ADAM17 
sheds multiple key oncogenic factors and that the shedding of these factors is 
increased following irradiation. Further, they identified ADAM17 as an important 
resistance mediator in response to IR. By means of these results, ADAM17 is involved 
in intra- and intercellular mechanism orchestrating radiation resistance, making it an 
interesting target for the combined treatment with ionizing radiation.  
 
In this study, we show the radiosensitizing effect of ADAM17-downregulation using an 
inducible shRNA system. Additionally, we provide first hints that ADAM17 is actively 
involved in intercellular communication, potentially being an important mediator of 
tumor progression. Our results support the rational of combining IR with ADAM17 
inhibitors because of the enzymes active contribution to radioresistance and tumor 
promoting intercellular communication.  
4.1 CHARACTERIZATION OF ADAM17-KNOCKDOWN CELLS 
To study the underlying molecular mechanism of how ADAM17 sensitizes towards IR, 
we generated NSCLC A549 and H358 cell lines containing a doxycycline-inducible 
expression of a shRNA targeting ADAM17 or a nontargeting shRNA. To visually 
distinguish the cells, for example by flow cytometry or immunofluorescence, the 
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vectors with the ADAM17-directed shRNAs contain an RFP tag, whereas the vector 
with the non-targeting shRNA is supplemented with a GFP tag. A population of A549 
cells showed approximately 90% of GFP or RFP positive cells (Figure 10). Each 
population showed approximately 10% negative cells, resulting either from cells 
surviving the puromycin selection without insertion of the plasmid because they 
developed intrinsic resistance or from cells whose expression of GFP or RFP 
respectively is hampered, resulting in very low or absent expression. To determine if 
the RFP or GFP negative cells also integrated the plasmid, we could have stained the 
cell populations with a conjugated-antibody against ADAM17 and gate for the 
ADAM17-expression on flow cytometry. Additionally, we could have sorted the cells 
via fluorescent-activated cell sorting (FACS) for the RFP or GFP positive cells, 
respectively, in order to obtain a population of cells with 100% expression of the 
respective fluorescent protein.  
 
We showed that the protein levels and activity of ADAM17 decrease prominently in 
Dox-induced A549 and H358 cells harboring the shADAM17 whereas the shNT did not 
affect ADAM17 protein levels or activity (Figure 11). Without the addition of DOX, there 
was no change in protein level, which indicates that the system is not active without 
doxycycline induction and of low leakage.  
Additionally, A549 and H358 shNT cells showed an increase in ADAM17 activity in a 
time dependent manner following IR, whereas in the A549 and H358 shADAM17 cells 
this increase was completely abrogated (Figure 12). The ADAM17-directed shRNA 
diminishes therefore not only the basal level of ADAM17, but also the radiation-
dependent increase of ADAM17.  
Amphiregulin has been reported as a direct substrate of ADAM17. [41] In order to prove 
the specificity of the shADAM17 system, we measured the amphiregulin concentration 
in the supernatant of our shRNA containing cell lines. In line with the reduction of 
ADAM17 enzyme activity, Amphiregulin was also reduced in the supernatant of 
shADAM17 cell lines compared to the shNT cell lines (Figure 13A). Interestingly, IR 
resulted in increased Amphiregulin shedding not only in shNT cells, but also in the 
shADAM17 cells (Figure 13B), although we did not observe an increase in ADAM17 
activity in the shADAM17 cells. This might indicate that upon irradiation, Amphiregulin 
might be cleaved independently from ADAM17.  
Together these results show the efficacy of the Tet-On system, as well as the specificity 
of shedding events mediated by ADAM17. We are therefore confident to consider 
these cells as ADAM17-knockdown cells and their secretome as “ADAM17-ligands 
scarce” and will continue using these genetically engineered cell lines.  
4.2 RADIOSENSITIZING EFFECT OF ADAM17 DEPLETION 
To cope with IR-induced cellular damage, tumor cells increase the proliferation in the 
surviving fraction and upregulate pro- survival signals, many of which are mediated by 
the IR-induced increased ADAM17 activity.[56] In theory, a cell lacking ADAM17 
enzyme activity is  less capable to cope with IR-induced cellular damage and is 
therefore more vulnerable to IR.  Here we showed that an ADAM17-knockdown A459 
cell population had a reduced baseline proliferative activity compared to a control cell 
population. Treatment with IR further decreased the overall proliferative activity of the 
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A549 ADAM17-knockdown cell population compared to control cells (Figure 14A). 
Interestingly, in the H358 cell line, the shADAM17 cell population had the same 
baseline proliferative activity as the shNT cell population, however upon irradiation a 
decrease of proliferative activity in shADAM17 cell population compared to a shNT cell 
population was also observed (Figure 14B). With the AlamarBlue assay we measure 
the overall proliferative activity of a cell population rather than the proliferative activity 
of an individual cell. It would therefore be interesting to assess if the decreased 
proliferative activity in ADAM17-knowdown cells is due to intrinsic mechanisms 
inhibiting the proliferation of individual cells or if it is a results of increased cell death in 
the ADAM17-knockdown cell populations resulting in fewer cells that can reduce 
AlamarBlue. Sharma et al. described another reason for the reduced proliferative 
activity, namely that upon treatment with IR, ADAM17 knockdown cells go into a 
senescent state. [41] Concomitantly with the increased radiosensitivity of A549 
shADAM17 cells as measured by the proliferative activity, the radiation-dose 
dependent clonogenicity also decreases compared to control cells (Figure 14C).  
From these results we conclude that ADAM17-depletion has a radiosensitizing effect 
on tumor cells. This synergistic effect on proliferative activity and clonogenic survival 
of irradiated ADAM17-knockdown cells in vitro might be the result of missing autocrine 
downstream receptor activation. ADAM17 is responsible for the cleavage of multiple 
ligands that can bind to receptors to activate various downstream signaling pathway - 
if the ligands are not cleaved, the corresponding growth promoting receptors will not 
be activated.  
Downstream receptor activation (e.g. EGFR phosphorylation status) can be used as 
surrogate marker to probe for autocrine receptor activation in response to IR. Sharma 
et al. performed experiments in which they analyzed EGFR phosphorylation over time 
after IR in control and siRNA-mediated ADAM17-knockdown cells. They saw 
enhanced EGFR phosphorylation in control cells compared to ADAM17-knockdown 
cells, and interestingly, also in cells that were subject to conditioned media derived 
from irradiated control or knockdown cells (siRNA). These results, together with the 
results from my master thesis, point to an ADAM17-regulated autocrine growth factor 
loop underlying the radioresistance of tumor cells.  
4.3 ADAM17 IS INVOLVED IN INTERCELLULAR SIGNALING PATHWAYS 
Besides the ADAM17 dependent autocrine signaling, we were also interested in the 
paracrine signaling. Therefore, the relevance of the overall ADAM17-dependent 
secretome to act in a paracrine way was investigated. More precisely, cellular 
migration, as one component of the paracrine signaling network, was analyzed.  
 
In a first experiment, we showed that A549 ADAM17-knockdown cells migrated 
significantly less than the shNT cells towards the same attractant, pointing to an 
ADAM17-dependent autocrine signaling network affecting migration capability (Figure 
15).  
 
Next, we tested whether ADAM17-cleaved factors influence the migration capability of 
surrounding cells. 
Here we showed in several experimental settings and to the best of our knowledge for 
the first time, that migration of A549 shNT cells is significantly reduced when exposed 
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to a secretome derived from non-irradiated or irradiated ADAM17-knockdown cells as 
compared to a secretome of non-irradiated or irradiated ADAM17-proficient cells 
(Figure 16 and 17). These results support the notion that ADAM17-cleaved factors 
have a paracrine influence on cellular migration.  
 
Irradiation influences cellular migration, although it is not clear whether it enhances or 
decreases cell migration in vitro. For the lung cancer cell line A549, some studies 
showed increased migration following IR [57, 58] while others showed decreased 
migration [59, 60]. We reported a slight decrease in migration of irradiated cells 
compared to non-irradiated cells exposed to a non-irradiated secretome coming from 
shNT cells (mean of 150 cells/field vs. mean of 117). Surprisingly, when the cells 
migrated towards a ligand-enriched secretome of shNT cells (generated by irradiation 
of secretome producing cells), we saw the opposite, namely a slightly higher migration 
of the irradiated cells compared to the non-irradiated cells. (mean of 163 vs. mean of 
148). In other words, the ligand-enriched secretome had no effect on the migration of 
non-irradiated cells (mean of 150 towards secretome coming from non-irradiated cells 
vs. mean of 148 towards secretome coming from irradiated cells, p>0.05), but it 
surprisingly increased the migration of irradiated cells (mean of 117 vs. mean of 163, 
p=0.013). The high complexity behind cellular migration as well as the low 
reproducibility of the transwell migration assay (resulting in high variance), make it 
difficult to draw any conclusions from the observed results. Nonetheless, we will use 
these preliminary results to further investigate the migration behavior of A549 in 
response to IR and towards a dose- and ADAM17-dependent secretome. Additionally, 
we will test the invasion capabilities of A549 in an in vitro invasion assay. Invasion 
capability can be linked more directly to the multistep process of metastasis, for though 
migration is a prerequisite for invasion, but not all migrating cells do also invade. [62] 
Reflecting on the results from the different transwell migration assays, we propose that 
ADAM17-cleaved factors are indeed involved in intra- and intercellular communication 
and migration. The factors either provide an environment more favorable for cancer 
cells, thus indirectly promoting migration towards the ligand-rich microenvironment, or 
an ADAM17-cleaved factor can directly promote migration by binding to a receptor 
whose downstream signaling events activate migration. In so far, the radiation-induced 
migration and invasion can at least in some part be attributed to ADAM17-mediated 
regulations. How exactly ionizing radiation influences the ADAM17-mediated signaling 
processes involved in migration will be addressed in future studies.  
Understanding the molecular mechanism behind migration and invasion will help to 
better comprehend the multi-step process of metastasis. Aggressiveness of tumors 
increases once they have acquired the capability to invade and metastasize to distant 
tissues and patients with metastasized tumors are faced with poorer prognosis. With 
its potential role in intercellular communication affecting migration, ADAM17 might 
represent a critical target not only for radiosensitization but also for reducing (IR-
induced) migration and invasion, altogether improving treatment outcome and patient 
survival.  
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4.4 OUTLOOK 
Our results support the rational for a combined treatment modality with a potent 
ADAM17-inhibitor. By inhibiting this highly active protease, NSCLC cells are sensitized 
towards IR and treatment outcome can potentially be improved. To strengthen these 
findings, additional experiments in vitro, and in vivo, are required.  
Since ADAM17 expression levels are increased in many different cancers compared 
to healthy tissue and correlated with poor prognoses, we will additionally study the 
functional effects of ADAM17 overexpression in order to gain more insights into the 
regulation of ADAM17 and its influence on auto- and paracrine signaling. We have 
therefore designed a lentiviral vector that we will use to transduce NSCLC cell lines. 
The transduced cell lines should then stably overexpress ADAM17. After 
characterization of the ADAM17 overexpression on the biochemical and cell biological 
level, we will test whether overexpression of ADAM17 promotes the survival upon 
irradiation.  
Furthermore, we will continue to study the intercellular communication mediated by 
ADAM17, because the results obtained during my master thesis clearly showed some 
involvement of ADAM17-cleaved factors. We will need to identify key ligands of 
ADAM17, acting in an auto- and/or paracrine way and consequently affecting tumor 
progression or even regression. A promising new method to screen for novel protein-
protein interactions is the BioID method. A biotin ligase is fused to a protein of interest, 
in our case ADAM17, where it can biotinylate proximal proteins. Biotinylation of 
proteins allows their selective isolation and identification. [61]  With this technique we 
can mark ADAM17-cleaved substrates and eventually identify relevant factors. This 
will shed light into the complex signaling network of ADAM17 and help to understand 
how it affects not only the tumor but also the surrounding tissue. 
 
As a closing remark, I want to say that theories and statements mounted in this thesis 
are based on preliminary data. To comply with high scientific standard, all experiments 
should be repeated. I hope my findings shed some light into the ongoing research of 
ADAM17 and will provide a baseline for future experiments done in this field of 
research.  
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